



DiagnosTear Ltd. – Approval to register patent to its TeaRx™ technology by the Israeli Patent Office

Tel Aviv (April 12, 2020) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. ("**DiagnosTear**")¹, that is engaged in research, development and commercialization of a product that is based on DiagnosTear's TeaRx™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film ("**Diagnostear Product**" and the "**TeaRx™ technology**"), announced that it received an approval to register a patent from the Israeli Patent Office (the "**Patent**").

The Patent joins similar patents approvals that were received by the European Patent Office and the US Patent and Trademark Office and constitute part of family of patent registration applications that were submitted in several markets, the main one being the US. The Patent protects the algorithm at the core of the Diagnostear Product and is based on the TeaRx Technology™ owned by Diagnostear.

The Patent strengthens and thickens the IP protection of the Diagnostear Product, the TeaRx™ Technology and the competitive position of Diagnostear.

The expected expiration date of the Patent, after registering, is May 2, 2036. The Patent is subject to payment of registration fee, as customary.

¹ Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).